Evidence map›Paper›PMID 33271790›Full record

ArticleJournal of personalized medicine2020

Diana L Lighezan, Anca S Bojan, Mihaela Iancu, Raluca M Pop, Ștefana Gligor-Popa, Florin Tripon, Adriana S Cosma, Ciprian Tomuleasa, Delia Dima, Mihnea Zdrenghea and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. The Role of DNA Repair (Medicina (Kaunas, Lithuania) · 2024
    Article
  3. TH open : companion journal to thrombosis and haemostasis · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Diana L LighezanDepartment of Hematology, "Victor Babeș" University of Medicine and Pharmacy, 2, Eftimie Murgu Square, 300041 Timișoara, Romania.
Anca S BojanDepartment of Hematology, The Oncology Institute "Ion Chiricuță", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Mihaela IancuDepartment of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-4557-5364
Raluca M PopDepartment of Pharmacology and Toxicology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0003-1899-5977
Ștefana Gligor-PopaDepartment of Genetics, The Oncology Institute "Ion Chiricuță", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
Florin TriponDepartment of Medical Genetics, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.ORCID 0000-0002-4297-9988
Adriana S CosmaDepartment of Medical Genetics, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.
Ciprian TomuleasaDepartment of Hematology, The Oncology Institute "Ion Chiricuță", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Delia DimaDepartment of Hematology, The Oncology Institute "Ion Chiricuță", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Mihnea ZdrengheaDepartment of Hematology, The Oncology Institute "Ion Chiricuță", "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Bogdan FeticaDepartment of Pathology, The Oncology Institute "Ion Chiricuță", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
Ioana IonițăDepartment of Hematology, "Victor Babeș" University of Medicine and Pharmacy, 2, Eftimie Murgu Square, 300041 Timișoara, Romania.
Ildikó O GaálDepartment of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Simona VișanDepartment of Genetics, The Oncology Institute "Ion Chiricuță", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.ORCID 0000-0001-7936-121X
Andreea-Manuela MireaDepartment of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Radu A PoppDepartment of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Mira FloreaDepartment of Community Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Cătălin AraniciuDepartment of Therapeutic Chemistry, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-8621-8662
Lucian PetrescuDepartment of Cardiology, "Victor Babeș" University of Medicine and Pharmacy, 2, Eftimie Murgu Square, 300041 Timișoara, Romania.
Ioan V PopDepartment of Medical Genetics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 8, Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Claudia BănescuDepartment of Medical Genetics, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 38, Gheorghe Marinescu Street, 540139 Târgu-Mureș, Romania.
Adrian P TrifaDepartment of Genetics, The Oncology Institute "Ion Chiricuță", 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · ROInstitute of Oncology Prof. Dr. Ion Chiricuta · ROUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROVictor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

Ministry of Research and Education, Romania PN-III-P1-1.1-PD-2016-1414
6 · The paper itself

Abstract

backgroundThe complexity of myeloproliferative neoplasms (MPNs) cannot be characterized by acquired somatic mutations alone. Individual genetic background is thought to contribute to the development of MPNs. The aim of our study was to assess the association between the

methodsWe evaluated the

resultsSignificant association between

conclusionsThe

Indexed as

genetic predispositionmyeloproliferative neoplasmssingle nucleotide polymorphismsTET2

Identifiers

PMID33271790
PMCPMC7711989
OpenAlexW3109314174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.